GlaxoSmithKline Plc expects profit to rise this year as the U.K. drugmaker prepares to spin off its consumer-health business, its biggest shake-up in more than two decades.
The company forecast earnings for the pharma and vaccines businesses to rise 12% to 14% in 2022 on an adjusted basis. The shares slipped 1.1% at 11 a.m. Wednesday in London as some investors worry about how long it will take for the company’s drug pipeline to deliver.
